PDCD1 and non-small cell lung carcinoma: Therefore, anti-PD-1/PDL-1 immune checkpoint inhibitors (ICIs) have been developed and investigated as anti-cancer therapy agents in various cancers, including melanoma, lymphoma, hepatocellular carcinoma, colorectal cancer, head, and neck squamous cell carcinoma, and NSCLC [17,18,19].